Abstract
Immunotherapy exploits the effector mechanisms of the immune system to combat cancer. A number of immunotherapeutic compounds are now firmly anchored in current treatment of cancer patients. For newly developed therapeutic entities, the study of the patient’s immune response to treatment remains an essential component of clinical trials.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
